Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) Jul 23
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), together with its subsidiaries (including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio is highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh, and both a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers (which the company is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet).
Allogeneic Immune Cell Generation Platform
Ability to manufacture immune effector cells (natural killer (NK) cells, macrophages) from cord blood derived CD34+ cells
Truly universal – no HLA matching required
Clinically Tested: Unmodified NK cells have been investigated in two phase 1 clinical trials
Universal SNAP-CAR
Antigen agnostic chimeric antigen receptor (CAR) platform
Universal SNAP-CAR construct binds to tagged antibodies directing antigen specificity and allowing for use of multiple antigens in the same indication
SNAP-CAR expression in a universal immune effector cell results in the ability to use ONE off-the-shelf SNAP-CAR cell bank for use with selected tagged antibodies across multiple indications such as hematological malignancies, solid tumors, and autoimmune diseases
GEAR Platform
GEAR: “Gene-Edited Antibody Resistant” cell engineering technology
Gene editing of immune effector cells to prevent fratricide when using therapeutic antibodies
GEAR editing does not impact normal function of non-modified cells
Development & Clinical Collaborations
